Chander Raman, Ph.D., an MS researcher and associate professor of clinical immunology and rheumatology at the University of Alabama at Birmingham, said the PreCISe findings confirm what neurologists have started to believe about managing CIS in adults – that treatment at the first clinical diagnosis of CIS is preferable to delay full conversion.